Illumina vs NGS Which Is a Smarter Choice?

Illumina and Next Generation Sequencing (NGS) stocks represent two different but related sectors within the genomics industry. Illumina is a leading provider of tools and systems for genetic sequencing, while NGS companies specialize in the development of next-generation sequencing technologies. Both sectors have seen significant growth in recent years due to increasing demand for genetic testing and research. Investors looking to capitalize on the booming genomics market may find opportunities in both Illumina and NGS stocks.

Illumina or NGS?

When comparing Illumina and NGS, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Illumina and NGS.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Illumina has a dividend yield of -%, while NGS has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, NGS reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Illumina P/E ratio at -14.81 and NGS's P/E ratio at -1.01. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Illumina P/B ratio is 11.05 while NGS's P/B ratio is 0.83.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Illumina has seen a 5-year revenue growth of 0.26%, while NGS's is -0.20%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Illumina's ROE at -42.15% and NGS's ROE at -73.16%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $140.67 for Illumina and kr3.04 for NGS. Over the past year, Illumina's prices ranged from $97.36 to $156.66, with a yearly change of 60.90%. NGS's prices fluctuated between kr2.86 and kr7.48, with a yearly change of 161.54%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.